DE69425662T2 - Als heilmittel nutzbare piperazin verbindungen - Google Patents

Als heilmittel nutzbare piperazin verbindungen

Info

Publication number
DE69425662T2
DE69425662T2 DE69425662T DE69425662T DE69425662T2 DE 69425662 T2 DE69425662 T2 DE 69425662T2 DE 69425662 T DE69425662 T DE 69425662T DE 69425662 T DE69425662 T DE 69425662T DE 69425662 T2 DE69425662 T2 DE 69425662T2
Authority
DE
Germany
Prior art keywords
utility
receptors
compounds
depression
piperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69425662T
Other languages
English (en)
Other versions
DE69425662D1 (de
Inventor
Kwen-Jen Chang
Joseph Bishop
Garrido Bubacz
Nutt Walton Mc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardent Pharmaceuticals Inc
Original Assignee
Delta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Pharmaceuticals Inc filed Critical Delta Pharmaceuticals Inc
Publication of DE69425662D1 publication Critical patent/DE69425662D1/de
Application granted granted Critical
Publication of DE69425662T2 publication Critical patent/DE69425662T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
DE69425662T 1993-07-30 1994-07-29 Als heilmittel nutzbare piperazin verbindungen Expired - Fee Related DE69425662T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9833393A 1993-07-30 1993-07-30
US16987993A 1993-12-17 1993-12-17
PCT/GB1994/001641 WO1995004051A1 (en) 1993-07-30 1994-07-29 Piperazine compounds used in therapy

Publications (2)

Publication Number Publication Date
DE69425662D1 DE69425662D1 (de) 2000-09-28
DE69425662T2 true DE69425662T2 (de) 2001-04-12

Family

ID=26794651

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69425662T Expired - Fee Related DE69425662T2 (de) 1993-07-30 1994-07-29 Als heilmittel nutzbare piperazin verbindungen

Country Status (18)

Country Link
US (1) US5552404A (de)
EP (1) EP0711289B1 (de)
JP (1) JPH09501156A (de)
CN (1) CN1054850C (de)
AT (1) ATE195733T1 (de)
AU (1) AU692788B2 (de)
CA (1) CA2168432C (de)
DE (1) DE69425662T2 (de)
DK (1) DK0711289T3 (de)
ES (1) ES2149881T3 (de)
GR (1) GR3034695T3 (de)
HU (1) HU221726B1 (de)
IL (1) IL110512A (de)
MY (1) MY111348A (de)
PT (1) PT711289E (de)
RU (1) RU2133744C1 (de)
TW (1) TW386081B (de)
WO (1) WO1995004051A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681830A (en) * 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
US5985880A (en) * 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5807858A (en) * 1996-06-05 1998-09-15 Delta Pharmaceutical, Inc. Compositions and methods for reducing respiratory depression
US6046200A (en) * 1994-09-09 2000-04-04 The United States Of America As Represented By The Secretary Of The Army Compositions having neuroprotective and analgesic activity
US6410537B1 (en) * 1994-09-09 2002-06-25 The United States Of America As Represented By The Secretary Of The Army Compositions having neuroprotective and analgesic activity
SE9504662D0 (sv) * 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9504661D0 (sv) * 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
GB9709972D0 (en) * 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
GB9804734D0 (en) * 1998-03-05 1998-04-29 Pfizer Ltd Compounds
US6359111B1 (en) 1998-05-28 2002-03-19 Neorx Corporation Opioid receptor targeting
WO1999065932A1 (en) 1998-06-18 1999-12-23 Sepracor, Inc. Tetrapeptides, analogs and peptidomimetics which bind selectively mammalian opioid receptors
SE9904673D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE9904674D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
US7115664B2 (en) * 2000-03-16 2006-10-03 Sepracor Inc. Peptidomimetic ligands for cellular receptors and ion channels
SE0001209D0 (sv) 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0100764D0 (sv) * 2001-03-07 2001-03-07 Astrazeneca Ab New assymetric process
WO2002080918A1 (fr) * 2001-04-02 2002-10-17 Toray Industries, Inc. Agent therapeutique ou prophylactique en cas de miction frequente ou d'incontinence urinaire
IL158631A0 (en) 2001-05-18 2004-05-12 Astrazeneca Ab 4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
RU2314809C2 (ru) * 2001-10-29 2008-01-20 Маунт Кук Байосайенсиз, Инк. Способ лечения депрессии соединениями-агонистами дельта-рецепторов
EP1469850B1 (de) 2002-01-02 2013-01-02 Versi Group, LLC Verfahren zur behandlung von sexuellen funktionsstörungen mit delta opioid-rezeptor-agonist-verbindungen
US6881829B2 (en) * 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
US8476280B2 (en) 2002-05-09 2013-07-02 Versi Group, Llc Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
AU2003240842A1 (en) * 2002-05-16 2003-12-02 Akzo Nobel N.V. Synergistic combination of an opioid analgesic and a nsaid
CN1202843C (zh) * 2002-06-21 2005-05-25 天大药业(深圳)有限公司 一种戒毒药物组合物及其制备方法和应用
WO2004007503A1 (ja) * 2002-07-11 2004-01-22 Toray Industries, Inc. 悪心・嘔吐の治療または予防剤
JP2006500282A (ja) * 2002-09-27 2006-01-05 コンチネンタル・テベス・アーゲー・ウント・コンパニー・オーハーゲー 調節可能なペダルブレーキ
SE0203303D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203302D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
US7314880B2 (en) * 2003-01-02 2008-01-01 Mount Cook Biosciences, Inc. Cardioprotective delta opioid receptor agonists and methods of using same
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
TWI317286B (en) 2003-12-31 2009-11-21 Targeting delivery system
MX2007001240A (es) 2004-08-02 2007-03-23 Astrazeneca Ab Derivados de diarilmetil-piperazina, preparaciones y usos de las mismas.
JP2008546638A (ja) * 2005-04-14 2008-12-25 マウント クック バイオサイエンシズ，インコーポレイテッド 新規なオピオイド化合物の組成物およびその使用方法
WO2008036858A2 (en) 2006-09-20 2008-03-27 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
CA2712731C (en) 2008-01-22 2016-05-03 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
MX2010012325A (es) * 2008-05-20 2010-12-02 Astrazeneca Ab Metodo para tratar trastorno ansioso depresivo mayor.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2630435A (en) * 1948-09-09 1953-03-03 Burroughs Wellcome Co N-benzohydryl-n-methyl piperazines and process of preparing same
US4518711A (en) 1983-05-16 1985-05-21 Gibson-Stephens Institute Conformationally constrained cyclic enkephalin analogs with delta receptor specificity
GB8320701D0 (en) 1983-08-01 1983-09-01 Wellcome Found Chemotherapeutic agent
IL78939A (en) 1986-01-17 1990-04-29 Robins Co Inc A H Pharmaceutical compositions containing n-substituted arylalkyl-and arylalkylene-piperidines and tetrahydropyridines and certain such novel compounds
ES2058265T3 (es) * 1987-04-16 1994-11-01 Lilly Co Eli Piperidinas antagonistas de opiaceos.
US4816586A (en) 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
KR920702620A (ko) * 1989-06-19 1992-10-06 엠. 피. 잭슨 암치료에 유용하며 항히스타민성 특성을 갖는 약물
EP0458160A3 (en) 1990-05-25 1992-03-18 Sociedad Espanola De Especialidades Farmaco-Terapeuticas, S.A. Substituted diphenylmethane derivatives as analgesic or anti-inflammatory agents
SE467304B (sv) * 1990-10-31 1992-06-29 Kamewa Ab Styr- och reverseringsanordning foer ett marint straaldriftsaggregat
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
IE914218A1 (en) * 1991-09-11 1993-03-24 Mcneilab Inc Novel 4-arylpiperazines and 4-arylpiperidines
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds

Also Published As

Publication number Publication date
CA2168432C (en) 2004-03-23
CA2168432A1 (en) 1995-02-09
US5552404A (en) 1996-09-03
MY111348A (en) 1999-11-30
DE69425662D1 (de) 2000-09-28
AU7235194A (en) 1995-02-28
HU221726B1 (hu) 2002-12-28
EP0711289B1 (de) 2000-08-23
IL110512A (en) 1998-10-30
JPH09501156A (ja) 1997-02-04
EP0711289A1 (de) 1996-05-15
GR3034695T3 (en) 2001-01-31
HUT72893A (en) 1996-06-28
DK0711289T3 (da) 2000-11-06
ATE195733T1 (de) 2000-09-15
PT711289E (pt) 2001-02-28
TW386081B (en) 2000-04-01
RU2133744C1 (ru) 1999-07-27
AU692788B2 (en) 1998-06-18
CN1133593A (zh) 1996-10-16
WO1995004051A1 (en) 1995-02-09
ES2149881T3 (es) 2000-11-16
HU9501982D0 (en) 1995-09-28
CN1054850C (zh) 2000-07-26
IL110512A0 (en) 1994-10-21

Similar Documents

Publication Publication Date Title
DE69425662T2 (de) Als heilmittel nutzbare piperazin verbindungen
CA2129046A1 (en) Opioid diarylmethylpiperazines and piperidines
ATE222754T1 (de) Ultrafeines pulver zur inhalation und dessen herstellung
DE69207526T2 (de) Tramadol N-Oxid, dessen Enantiomere und Zusammensetzungen davon, und deren Verwendung
RS52283B (sr) 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilkarbonil)-n- metil-amino)-anilino)-1-fenil-metilen]-6-metoksikarbonil-2- indolinon-monoetansulfonat i njegova primena u farmaceutskoj kompoziciji
RS51013B (sr) Indolinon supstituisan na poziciji 6, njegovo dobijanje i njegova upotreba kao leka
IL139080A0 (en) Btx inhibitors and methods for their indentification and use
NZ524248A (en) Spray device
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
DE122004000016I2 (de) Schadpilzbakampfung mit der kombination eines die atmung am cytochrom-komplex III hemmenden wirkstoffes mit einem amid.
DE69531038D1 (de) Adsorptionskörper enthaltend Aktivkohle, aktiviertes Aluminiumoxid und einen anorganischen Binder und Methode zu dessen Herstellung
BR0213608A (pt) Composição oral
WO2001048845A3 (de) Brennstoffzellenstack, verfahren zu dessen montage und verwendung eines solchen brennstoffzellenstacks
DE69022501D1 (de) Verwendung eines Amylinantagonisten zur Herstellung eines Artzneimittels zur Behandlung von Fettsucht und essentieller Hypertonie und damit zusammenhängenden Krankheiten.
PL360692A1 (en) Process of injection moulding a syringe from polythylene wax containing polypropylene, syringe obtained thereby and particulate composition therefor
EP2260843A3 (de) Alpha-MSH und Derivate zur Induktion von Antigentoleranz
MXPA04004477A (es) Antagonistas del neuropeptido neuroquinina-1(nk1).
WO2000045857A3 (de) Metallmakrozyklen für zweischritt-strahlentherapieformen
DE69602087D1 (de) 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten
DE59912402D1 (de) Polycyclische thiazolidin-2-yliden amine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
NZ335052A (en) Piperazino derivatives as neurokinin antagonists
ATE414734T1 (de) Russe und deren verwendung
Font et al. Finding the words: Instruments for a therapy of liberation
NO20013118D0 (no) Anvendelse av en 5HT2A og 5HT2A/C reseptor-antagonist for fremstilling av medisiner for behandling av snorking og syndrommed höy motstand i övre anatomiske luftveier
Rubsam et al. Development of compensatory mitigation wetlands for landfill expansion

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ARDENT PHARMACEUTICALS,INC., CHAPEL HILL, NORTH CA

8339 Ceased/non-payment of the annual fee